The company, which provides clinical resource management and revenue cycle management solutions for the health-care industry, reported earnings per share of 30 cents for the quarter. Revenue increased 4% year over year to $170.5 million thanks to a 7% increase in its clinical resource management segment and a 1% decrease in its revenue cycle management segment. Analysts' consensus estimate called for 28 cents a share on revenue of $165.7 million.
MedAssets forecast revenue growth of 2.9% to 4.9% to a range of $700 million to $714 million. The company also expects earnings per share of $1.33 to $1.43. These figures are in line with the consensus estimate.
Finally, the company's board of directors announced a plan to repurchase $75 million of its own shares during the next 12 months.
TheStreet Ratings team rates MEDASSETS INC as a "hold" with a ratings score of C. TheStreet Ratings Team has this to say about their recommendation:
"We rate MEDASSETS INC (MDAS) a HOLD. The primary factors that have impacted our rating are mixed - some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income and revenue growth. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk, disappointing return on equity and weak operating cash flow."